Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINHALATIONGeneric

SEEBRI NEOHALER

GLYCOPYRROLATE

Standard Dose
15.6MCG/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview SEEBRI NEOHALER is listed in Drugs@FDA under application 207923 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient GLYCOPYRROLATE Form and strength POWDER;INHALATION - 15.6MCG/INH Sponsor NOVARTIS Submission history Latest submission status date: 2021-07-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview SEEBRI NEOHALER is listed in Drugs@FDA under application 207923 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient GLYCOPYRROLATE Form and strength POWDER;INHALATION - 15.6MCG/INH Sponsor NOVARTIS Submission history Latest submission status date: 2021-07-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.